These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Autoimmunity in kidney diseases.
    Author: Kettritz R.
    Journal: Scand J Clin Lab Invest Suppl; 2008; 241():99-103. PubMed ID: 18569975.
    Abstract:
    Renal involvement in autoimmunity has many facets. Glomerular, tubular and vascular structures are targeted and damaged as a consequence of autoimmune processes. Most dramatic and life-threatening causes are observed with diseases that result in rapidly progressive glomerulonephritis (GN), frequently accompanied by involvement of additional non-renal organs. Typical diseases with these characteristics are anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitidis, anti-glomerular basement membrane (anti-GBM) GN and proliferative lupus nephritis. The leading cause of rapidly progressive GN is ANCA-associated GN and is the main focus of this article. Two major ANCA antigens have been described, namely proteinase 3 (PR3), with a cytoplasmic immunfluorescence staining pattern, and myeloperoxidase (MPO), with a perinuclear pattern. ANCA-associated diseases include Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS) and a renal limited disease form that presents solely with necrotizing crescentic GN. Because of the strong ANCA association with the aforementioned diseases, ANCA has become a valuable diagnostic tool for clinicians. Moreover, a variety of in vitro and in vivo findings have established the causal role of ANCA in the disease development. Recently, the membrane-PR3 expression pattern on neutrophils was shown to have clinical significance, suggesting membrane-PR3 as a novel biomarker. Furthermore, the data demonstrate that membrane-PR3 expression is restricted to a stable subset of neutrophils. This subset is determined by the existence of the glycosylphosphatidylinositol (GPI)-anchored NB1 receptor (CD177). Better understanding of the PR3-NB1 interaction may have therapeutic implications with the development of more selective drugs.
    [Abstract] [Full Text] [Related] [New Search]